Analysts Expect United Therapeutics Co. (UTHR) to Post $3.37 EPS
Brokerages predict that United Therapeutics Co. (NASDAQ:UTHR) will report earnings of $3.37 per share for the current quarter, according to Zacks. Five analysts have made estimates for United Therapeutics’ earnings, with the highest EPS estimate coming in at $4.34 and the lowest estimate coming in at $2.80. United Therapeutics posted earnings of $6.27 per share during the same quarter last year, which would suggest a negative year over year growth rate of 46.3%. The firm is expected to announce its next earnings results on Wednesday, October 24th.
According to Zacks, analysts expect that United Therapeutics will report full-year earnings of $13.71 per share for the current fiscal year, with EPS estimates ranging from $12.66 to $15.00. For the next fiscal year, analysts expect that the business will report earnings of $11.14 per share, with EPS estimates ranging from $8.08 to $13.59. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for United Therapeutics.
United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.57 by $1.41. The firm had revenue of $444.50 million during the quarter, compared to analyst estimates of $368.63 million. United Therapeutics had a return on equity of 34.42% and a net margin of 40.87%. The business’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.37 earnings per share.
NASDAQ:UTHR traded down $2.16 on Friday, hitting $123.92. 382,041 shares of the stock were exchanged, compared to its average volume of 429,416. United Therapeutics has a fifty-two week low of $100.57 and a fifty-two week high of $152.55. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.64 and a quick ratio of 4.35. The firm has a market capitalization of $5.57 billion, a PE ratio of 11.38, a P/E/G ratio of 28.86 and a beta of 1.28.
In other news, Director Richard Giltner sold 3,240 shares of the stock in a transaction that occurred on Thursday, August 16th. The stock was sold at an average price of $129.38, for a total transaction of $419,191.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Judy D. Olian sold 600 shares of the stock in a transaction that occurred on Tuesday, June 12th. The stock was sold at an average price of $112.38, for a total value of $67,428.00. The disclosure for this sale can be found here. Insiders have sold a total of 7,080 shares of company stock worth $852,966 over the last quarter. Insiders own 8.20% of the company’s stock.
Several institutional investors have recently made changes to their positions in UTHR. HL Financial Services LLC raised its position in shares of United Therapeutics by 40.2% during the 1st quarter. HL Financial Services LLC now owns 2,053 shares of the biotechnology company’s stock worth $231,000 after purchasing an additional 589 shares during the period. NuWave Investment Management LLC raised its position in shares of United Therapeutics by 13,112.5% during the 1st quarter. NuWave Investment Management LLC now owns 1,057 shares of the biotechnology company’s stock worth $116,000 after purchasing an additional 1,049 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of United Therapeutics by 0.7% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 125,363 shares of the biotechnology company’s stock worth $14,086,000 after purchasing an additional 933 shares during the period. Westpac Banking Corp raised its position in shares of United Therapeutics by 455.2% during the 1st quarter. Westpac Banking Corp now owns 13,975 shares of the biotechnology company’s stock worth $1,570,000 after purchasing an additional 11,458 shares during the period. Finally, DekaBank Deutsche Girozentrale raised its position in shares of United Therapeutics by 7.8% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 75,834 shares of the biotechnology company’s stock worth $8,454,000 after purchasing an additional 5,509 shares during the period. Institutional investors and hedge funds own 99.59% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Story: Asset Allocation, Balancing Your Investments
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.